News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Amarin Corporation PLC (AMRN) Announces Submission of Supplemental New Drug Application for Novasep as Fourth Vascepa® Active Pharmaceutical Ingredient Supplier


8/26/2013 9:37:42 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 26, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the submission of a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for Novasep Group, S.A.S., through its subsidiary Finorga S.A.S., as an additional Vascepa® (icosapent ethyl) active pharmaceutical ingredient (API) supplier. Novasep is part of the previously disclosed Slanmhor consortium with which Amarin announced a global supply agreement in 2012.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES